Related Experiment Videos
FK506 controls CD40L-induced systemic autoimmunity in mice
Karin Loser1, Sandra Balkow, Tetsuya Higuchi
1Department of Dermatology, University of Münster, Münster, Germany. loserk@uni-muenster.de
The Journal of Investigative Dermatology
|February 14, 2006
Summary
The immunosuppressant FK506 effectively treats systemic autoimmunity in CD40-CD40 ligand (CD40L) transgenic mice. FK506 reduces dermatitis, autoantibodies, and restores renal function, demonstrating its therapeutic potential.
Area of Science:
- Immunology
- Pharmacology
- Autoimmune Diseases
Background:
- Autoimmunity arises from failed self-tolerance mechanisms.
- CD40-CD40 ligand (CD40L) interaction can disrupt established immunotolerance.
- CD40L transgenic mice spontaneously develop a mixed connective tissue-like disease.
Purpose of the Study:
- To investigate the therapeutic effects of calcineurin-inhibitor FK506 on CD40L-induced systemic autoimmunity.
- To assess FK506's impact on autoimmune manifestations in CD40L transgenic mice.
Main Methods:
- CD40L transgenic mice with established autoimmunity were treated with FK506.
- Evaluated autoimmune dermatitis scores, leukocyte infiltration, lymphadenopathy, and CD8+ T cell activation markers.
- Measured autoantibody titers and proteinuria to assess renal function.
Main Results:
- FK506 treatment significantly reduced autoimmune dermatitis and leukocyte infiltration.
- Diminished lymphadenopathy and suppressed cytotoxic/autoreactive CD8+ T cell development were observed.
- FK506 lowered autoantibody titers and improved renal function, indicated by reduced proteinuria.
Conclusions:
- FK506 demonstrates significant therapeutic benefits in treating CD40L-induced systemic autoimmunity.
- The findings highlight FK506's efficacy in suppressing ongoing severe autoimmune responses.
- FK506 holds promise as a treatment for autoimmune disorders.